Prostate Specific Antigen News and Research

RSS

Lowering the current PSA threshold for recommending a prostate biopsy may subject millions of men to unnecessary, potentially harmful medical procedures

Lowering the current prostate-specific antigen (PSA) threshold for recommending a prostate biopsy may subject millions of men to unnecessary, potentially harmful medical procedures with no evidence that it will improve prostate cancer mortality rates, according to a new study in the August 3 issue of the Journal of the National Cancer Institute.

2 Aug 2005

Clinical factors can help predict the risk of prostate cancer death for patients following a radical prostatectomy

Clinical factors including the time to biochemical recurrence following surgery can help predict the risk of prostate cancer death for patients following a radical prostatectomy, according to a study in the July 27 issue of JAMA: The Journal of the American Medical Association.

27 Jul 2005

Tool helps determine who is at high risk of death after prostate cancer recurrence following surgery

Researchers at Johns Hopkins and The Brady Urological Institute have identified three risk factors and developed a simple reference tool that doctors can use to determine who is at high risk of death after prostate cancer recurrence following surgery.

26 Jul 2005

Cancer vaccine combined with hormone-deprivation therapy can help patients with recurrence of prostate cancer

A new study finds that a cancer vaccine combined with hormone-deprivation therapy can help patients with recurrence of prostate cancer. The results of this clinical trial, led by scientists at the National Cancer Institute (NCI), part of the National Institutes of Health, appear in the August 2005 issue of the Journal of Urology.

26 Jul 2005

No single PSA level ensures safety from prostate cancer risk

Ian M. Thompson Jr., M.D., professor and chair of urology at the U T Health Science Center, is looking for a better test - or set of tests - to diagnose prostate cancer and to distinguish between cancers that will kill men if left untreated and those that will not threaten health and do not need treatment.

19 Jul 2005

PSA screening of asymptomatic men reduced risk of metastatic prostate cancer by 35 per cent

Early screening of prostate cancer in asymptomatic men may reduce their risk of death from metastatic prostate cancer by as much as 35 per cent, researchers from the University of Toronto have found.

11 Jul 2005

True validity of prostate cancer tests questioned

According to the American cancer society, more than 232,000 men will be diagnosed with prostate cancer this year, and about 30,000 will die of it.

11 Jul 2005

Accuracy of PSA screening for detecting prostate cancer

A new study indicates there is no specific PSA value that has both high sensitivity and high specificity for monitoring healthy men for prostate cancer, but rather there is a continuum of prostate cancer risk at all values of PSA, according to a study in the July 6 issue of JAMA: The Journal of the American Medical Association.

6 Jul 2005

Obesity appears to increase the risk of prostate cancer

The obesity study examined the association between body mass index - weight to height ratio - and prostate cancer in 787 men undergoing biopsy due to an elevated tumor marker in the blood or an abnormal physical exam at a Veterans Affairs hospital in California between 1998 and 2002.

23 May 2005

Vitamin D, taxotere combination promising for advanced prostate cancer

Results of a new study strongly suggest that DN-101, a new high-dose calcitriol pill designed specifically as a cancer therapy, given in combination with docetaxel (Taxotere) extends the lives of men with advanced prostate cancer.

17 May 2005

Identifying high-risk prostate cancer means more prudent treatment decisions

While prostate cancer is a very common diagnosis, it is a deadly disease in relatively few men. One in 6 men will develop prostate cancer during his lifetime. However, of these, only one in 10 cases will be life-threatening.

16 May 2005

Study examines influence of celebrity endorsements of cancer screening

More than one-half of adults surveyed nationwide had seen or heard celebrity endorsements of cancer screening tests, and more than one-fourth of those who had seen or heard an endorsement reported that it made them more likely to undergo the promoted screening test, according to a new study in the May 4 issue of the Journal of the National Cancer Institute.

3 May 2005

Breast cancer gene may play a major role in the recurrence of prostate cancer

A gene associated with breast cancer also may play a major role in the recurrence of prostate cancer, according to new research from the University of North Carolina at Chapel Hill School of Medicine and UNC Lineberger Comprehensive Cancer Center.

20 Apr 2005

Innovative urine test for highly specific prostate cancer gene shows promise

Gen-Probe's prototype urine test for PCA3 gene expression may help improve the diagnosis of prostate cancer, according to three early-stage studies presented as posters at the American Association for Clinical Chemistry's 37th Annual Oak Ridge Conference and the Annual Meeting of the American Association for Cancer Research (AACR).

20 Apr 2005

cT3 prostate cancer is operable

New findings from Mayo Clinic indicate that cT3 prostate cancer, a disease in which the cancer has spread locally from inside the prostate to immediately outside it, is operable and has 15-year cancer survival rates of almost 80 percent.

3 Apr 2005

Social and cultural factors play a significant role in the treatment decisions of patients with prostate cancer

Marital status, high school education, and race/ethnicity may play a far greater role in patients' treatment decisions than previously believed.

28 Mar 2005

Demonstrating cost and clinical benefits critical to expansion of European seed brachytherapy markets

The nascent European seed brachytherapy market has been grappling with issues of high procedural and investment costs and a lack of local clinical evidence. However, growing evidence of the overall clinical and cost benefits of seed brachytherapy coupled with rising patient awareness is set to boost market expansion.

21 Mar 2005

Uncertainty about the need for prostate cancer

Initial results from an ongoing study evaluating the benefit of prostate cancer screening practices demonstrate that the combined use of both standard tests - the prostate-specific antigen (PSA) blood test and the digital rectal exam (DRE) - is optimal for detecting cancer.

16 Mar 2005

Cryoablation effective, safe, durable treatment for prostate cancer

Endocare today announced that 10-year follow-up data from a retrospective study demonstrated that cryoablation as a treatment for prostate cancer has a biochemical disease free survival rate of 77 percent.

14 Mar 2005

Prostate screenings could be used to encourage colon checks

Colon cancer is the third leading cause of cancer death in men, but according to a new University of Michigan Health System study, fewer than half of men surveyed were up-to-date with colon cancer screenings.

3 Mar 2005